Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mimedx Group Inc (MDXG)

Mimedx Group Inc (MDXG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MiMedx Group, Inc. Announces Regulatory Changes Impacting Coverage for Skin Substitute Grafts

Revised LCDs will eliminate coverage for over 200 unproven skin substitutes, promoting clinically validated treatments.Quiver AI SummaryMiMedx Group, Inc. announced that over 200 unproven skin substitute...

MDXG : 9.22 (+1.77%)
MIMEDX’s Advocacy to Rein in Runaway Medicare Spend for Skin Substitutes Has Yielded Significant Results with Planned Implementation of LCDs

MDXG : 9.22 (+1.77%)
MIMEDX to Participate in Upcoming Investor Conferences

MDXG : 9.22 (+1.77%)
MiMedx: Q3 Earnings Snapshot

MiMedx: Q3 Earnings Snapshot

MDXG : 9.22 (+1.77%)
MIMEDX Announces Third Quarter 2024 Operating and Financial Results

MDXG : 9.22 (+1.77%)
MIMEDX to Host Third Quarter 2024 Operating and Financial Results Conference Call on October 30

MDXG : 9.22 (+1.77%)
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue

MDXG : 9.22 (+1.77%)
MiMedx: Q2 Earnings Snapshot

MiMedx: Q2 Earnings Snapshot

MDXG : 9.22 (+1.77%)
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth

MiMedx Group, Inc. (NASDAQ: MDXG) is engaged as a biotechnology company that is focused as a placental biologics developer to

MDXG : 9.22 (+1.77%)
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027

EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END

VCEL : 56.71 (-0.96%)
OCEL : 2.7500 (unch)
BRTX : 1.4450 (+3.21%)
MDXG : 9.22 (+1.77%)
NNVC : 1.2800 (-3.76%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar